Prosthesis Infection and One-step Exchange: Pretreatment by Targeted Antibiotic Therapy in At-risk Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03848091|
Recruitment Status : Completed
First Posted : February 20, 2019
Last Update Posted : February 20, 2019
One-step exchange arthroplasty is more and more used in the treatment of chronic infections, especially in patients at risk anesthetic.
This strategy is not recommended in patients infected with multidrug-resistant organisms or difficult to treat because of a risk of bacterial persistence on the new implant.
Antibiotic pretreatment by a narrow-spectrum molecule and for which resistance acquisition is difficult might be of interest to try to reduce the inoculum and avoid contamination of the new implant.
|Condition or disease||Intervention/treatment|
|Prosthetic Joint Infection Antibiotic Resistant Infection||Other: Antibiotic pretreatment|
|Study Type :||Observational|
|Actual Enrollment :||13 participants|
|Official Title:||Prosthesis Infection and One-step Exchange: Pretreatment by Targeted Antibiotic Therapy in|
|Actual Study Start Date :||April 1, 2016|
|Actual Primary Completion Date :||January 1, 2018|
|Actual Study Completion Date :||January 1, 2018|
patients having had an antibiotic pretreatment before a one-step exchange arthroplasty
Other: Antibiotic pretreatment
a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)
- Rate of Treatment Failure [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
- rate of use of this strategy [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]descriptions of patients managed with this strategy
- rate of bacteria responsible for infection [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]bacterial epidemiology
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03848091
|Hospices Civils de Lyon|
|Lyon, France, 69004|
|Principal Investigator:||Tristan Ferry, Md,PhD||HCL|